4D Path Adds Industry Vets, Secures Funds to Scale AI Cancer Platform

NEWTON, Mass. – May 05, 2026 – In a strategic move signaling a shift from development to aggressive growth, personalized oncology firm 4D Path has announced the first close of a new financing round and the appointment of two seasoned biopharmaceutical executives to its Board of Directors. Katherine Vega Stultz, an oncology commercialization veteran, will take the helm as Board Chair, while Robert J. Hombach, a renowned financial and operational leader, also joins the board. The dual announcement underscores the company's ambition to accelerate the deployment of its groundbreaking cancer therapy prediction platform, the Q-Plasia OncoReader (QPOR™).

The infusion of new capital, coupled with the high-caliber leadership, is set to catalyze the company’s mission to change how cancer treatment is selected. 4D Path aims to provide oncologists with predictive tools that offer clear, accurate guidance on which therapies will work for a specific patient, moving beyond the traditional one-size-fits-all approach.

A New Era of Leadership and Capital

The appointments of Stultz and Hombach are a clear signal to the market that 4D Path is preparing for its next major phase of clinical validation and commercial expansion. Their combined expertise addresses the two most critical pillars for a growing biotech: clinical and commercial strategy, and financial and operational excellence.

Katherine Vega Stultz brings decades of experience translating scientific innovation into clinical and commercial success. During her tenure at Celgene, she was instrumental in launching multiple multi-billion-dollar products and oversaw a global clinical project organization with over 30 mid-to-late-stage programs in hematology and oncology. Her deep understanding of the journey from “bench to bedside” is considered a monumental asset for 4D Path as it seeks to embed its technology in clinical workflows and forge biopharma partnerships. “I am thrilled to be a part of the 4D Path growth story,” Stultz stated in the announcement. “[This] is a critical unmet need for medical oncologists and a development challenge as companies progress their clinical strategies.”

Complementing Stultz’s scientific and commercial acumen is Robert J. Hombach’s extensive financial and operational leadership. Hombach is highly regarded for his role as Executive Vice President, CFO, and COO of Baxalta, where he was instrumental in its successful spin-off from Baxter International and its eventual $32 billion acquisition by Shire. His experience serving on the boards of major public companies like BioMarin provides 4D Path with the rigorous financial stewardship required to scale operations and navigate complex market dynamics. “I am very excited to join the Board of 4D Path as the company builds a compelling growth trajectory of tremendous potential benefit for patients, providers, drug developers, and investors,” Hombach commented.

Jacopo Leonardi, CEO of 4D Path, emphasized the synergy of the new appointments. “Katherine’s deep expertise in oncology strategy, R&D, and commercialization coupled with Bob’s company strategy, financial and operational expertise perfectly complement the outstanding group of leaders on our board,” he said. “Their addition coupled with our strategic financing will serve as a catalyst to bring this promising treatment predictive technology one step closer to helping patients around the world beat cancer.”

While the company did not disclose the amount of the new strategic financing, it builds on a solid foundation of previous funding rounds totaling over $19 million, positioning 4D Path to significantly ramp up its clinical and partnership activities.

The QPOR Engine: Redefining Prediction with Physics

At the heart of 4D Path's strategy is its patented Q-Plasia OncoReader (QPOR™), a platform that represents a paradigm shift in predictive oncology. Unlike genomic or molecular tests that require specialized tissue processing, QPOR™ leverages a novel, physics-informed approach to analyze digitized images of routine, H&E-stained biopsy slides—the most common type of tissue sample in pathology.

This method allows the platform to directly measure and quantify the dynamics of cell cycle deregulation and the tumor's immune microenvironment from a pre-treatment sample. By analyzing these fundamental biological processes, QPOR™ can predict a tumor’s response to a specific therapy, such as chemotherapy or immunotherapy, before the first dose is ever administered. This could save patients from enduring the toxicity of ineffective treatments and allow oncologists to pivot to more promising options sooner.

The company has validated its platform with a remarkable track record, touting “six for six” successes in delivering clinically relevant results across diverse cancers including breast, ovarian, colorectal, and skin cancer. The technology has shown efficacy across different disease stages and with both standard-of-care and investigational therapies.

Perhaps the most compelling evidence comes from its work in Triple-Negative Breast Cancer (TNBC), an aggressive and difficult-to-treat subtype. In a study published in the prestigious Journal of the National Cancer Institute (JNCI) and presented at the American Society of Clinical Oncology (ASCO) meeting, QPOR™ demonstrated over 80% accuracy in predicting patient response to neoadjuvant chemotherapy. This represents a monumental improvement over the roughly 40% accuracy of the current standard of care. The platform has also shown significant promise in metastatic melanoma, where it identified a subset of patients who gained a median of over six years in overall survival from immunotherapy that they might not have otherwise received.

Navigating a Competitive and Collaborative Landscape

4D Path enters this next phase in a dynamic and highly competitive market. The field of AI-driven diagnostics and digital pathology is booming, with companies like Tempus and PathAI attracting massive investment and forging extensive partnerships. The recent acquisition of PathAI by pharmaceutical giant Roche for over $1 billion highlights the immense value that industry leaders place on AI tools that can de-risk drug development and enable more precise patient diagnosis.

However, 4D Path's strategy appears to be as much about collaboration as it is about competition. The press release explicitly states that the new funding will accelerate the development of biomarkers for “partnerships with Biopharma companies.” This aligns perfectly with a major industry trend: pharmaceutical companies are increasingly desperate for reliable biomarkers to improve the efficiency and success rate of clinical trials. The ability to accurately select patients most likely to respond to a new drug can save billions of dollars and years of development time.

This is where the QPOR™ platform’s unique advantages become a powerful negotiating tool. Its ability to generate predictive insights from standard, universally available H&E slides makes it an easily scalable solution for global clinical trials. By identifying responders and non-responders upfront, 4D Path can help biopharma partners design smarter, more targeted studies and develop companion diagnostics for their novel therapies.

With a validated technology, fresh capital, and now a board fortified with world-class expertise in scaling oncology ventures, 4D Path is strategically positioned for a pivotal chapter. The company is making a clear and calculated transition from a promising research entity to a formidable commercial player, poised to make a tangible impact on the future of personalized cancer care.